Home Cart 0 Sign in  

[ CAS No. 19545-26-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 19545-26-7
Chemical Structure| 19545-26-7
Structure of 19545-26-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 19545-26-7 ]

Related Doc. of [ 19545-26-7 ]

Alternatived Products of [ 19545-26-7 ]

Product Details of [ 19545-26-7 ]

CAS No. :19545-26-7 MDL No. :MFCD00133927
Formula : C23H24O8 Boiling Point : -
Linear Structure Formula :- InChI Key :QDLHCMPXEPAAMD-QAIWCSMKSA-N
M.W : 428.43 Pubchem ID :312145
Synonyms :
SL-2052;KY 12420;NSC 627609;BRN 0067676
Chemical Name :(1S,6bR,9aS,11R,11bR)-1-(Methoxymethyl)-9a,11b-dimethyl-3,6,9-trioxo-1,6,6b,7,8,9,9a,10,11,11b-decahydro-3H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate

Calculated chemistry of [ 19545-26-7 ]

Physicochemical Properties

Num. heavy atoms : 31
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.57
Num. rotatable bonds : 4
Num. H-bond acceptors : 8.0
Num. H-bond donors : 0.0
Molar Refractivity : 105.71
TPSA : 109.11 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -8.08 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.7
Log Po/w (XLOGP3) : 1.18
Log Po/w (WLOGP) : 2.54
Log Po/w (MLOGP) : 0.94
Log Po/w (SILICOS-IT) : 3.64
Consensus Log Po/w : 2.2

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.1
Solubility : 0.344 mg/ml ; 0.000803 mol/l
Class : Soluble
Log S (Ali) : -3.07
Solubility : 0.367 mg/ml ; 0.000857 mol/l
Class : Soluble
Log S (SILICOS-IT) : -5.15
Solubility : 0.00301 mg/ml ; 0.00000703 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 5.66

Safety of [ 19545-26-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P271 UN#:N/A
Hazard Statements:H302+H332 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 19545-26-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 19545-26-7 ]

[ 19545-26-7 ] Synthesis Path-Downstream   1~9

  • 1
  • [ 1927-25-9 ]
  • [ 19545-26-7 ]
  • 2-[(1S,10R,11R,13S,14R)-11-Acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[a]phenanthren-(4Z)-ylidenemethyl]-amino}-4-hydroxy-butyric acid [ No CAS ]
  • 2
  • [ 7200-25-1 ]
  • [ 19545-26-7 ]
  • 2-[(1S,10R,11R,13S,14R)-11-Acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[a]phenanthren-(4Z)-ylidenemethyl]-amino}-5-guanidino-pentanoic acid [ No CAS ]
  • 3
  • [ 106-60-5 ]
  • [ 19545-26-7 ]
  • 5-[(1S,10R,11R,13S,14R)-11-Acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[a]phenanthren-(4Z)-ylidenemethyl]-amino}-4-oxo-pentanoic acid [ No CAS ]
  • 4
  • [ 22059-21-8 ]
  • [ 19545-26-7 ]
  • 1-[(1S,10R,11R,13S,14R)-11-Acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[a]phenanthren-(4Z)-ylidenemethyl]-amino}-cyclopropanecarboxylic acid [ No CAS ]
  • 5
  • [ 1034-10-2 ]
  • [ 19545-26-7 ]
  • 2-[(11-acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[<i>a</i>]phenanthren-4-ylidenemethyl)-amino]-3-[4-(4-hydroxy-phenoxy)-phenyl]-propionic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
In dimethyl sulfoxide at 20 - 58℃;
  • 6
  • [ 19545-26-7 ]
  • [ 704-15-4 ]
  • (S)-1-(2-[(1S,10R,11R,13S,14R)-11-Acetoxy-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,7,10,11,12,13,14,15,16,17-decahydro-2-oxa-cyclopenta[a]phenanthren-(4Z)-ylidenemethyl]-amino}-acetyl)-pyrrolidine-2-carboxylic acid [ No CAS ]
  • 7
  • [ 19545-26-7 ]
  • [ 60-32-2 ]
  • wortmannin C20-NH-hexanoic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
76% With triethylamine In dimethyl sulfoxide at 20℃; 2 Wortmannin (42.8 mg, 0.1 mmol), 6-aminohexanonic acid, referred to as 6-NH-hexanoic acid (65.5 mg, 0.5 mmol) and triethylamine (20 μl) were mixed in anhydrous DMSO (1 mL). The mixture was stirred at room temperature till complete (TLC monitoring). The final solution was purified by reverse phase HPLC with acetonitrile and water as solvents. The injection mixture was made by mixing reaction mixture with acetonitrile (containing 50% water) by 1 : 1 ratio just before the injection. After lyophilization, a yellow powder is obtained. 42.5 mg, 76.0%. MS: C29H37NOi0, cal. 560.2495 (M+H1"), found 560.2499; IH NMR, (CDCl3): 0.828 (3H, s, Cl 8-CH3), 1.430-1.507 (2H, m, -CH2CH2CH2-), 1.532 (3H, s, C19-CH3), 1.677-1.751 (4H, m, - CH2CH2CH2-), 1.859-1.904 (IH, dd, Jl=14.8Hz, J2=2.8Hz, H-12), 2.050 (3H5 s, CH3CO), 2.238-2.373 (3H, m, H-15, H-16), 2.416 (2H, t, J=7.4Hz, CH2CH2COOH), 2.542-2.629 (IH, m, H-12), 2.835-2.880(1H, m, CH3OCH2), 2.944-2.989 (IH, m, H-14), 3.137-3.259 (2H, m, H-15, CH3OCH2), 3.275 (3H, s, CH3OCH2), 3.417 (2H, q, Jl=13.0Hz, J2=6.5Hz), 4.328-4.345 (IH, m, H-I), 4.840 (2H, broad, OH), 5.982-6.009 (IH, m, H-11), 8.553 (IH, d, J=I 3.9Hz, H- 20), 9.810-9.920 (IH, m, NH). 13C NMR: 16 .839, 21.143, 22.593, 24.287, 26.049, 26.431, 30.452, 33.619, 36.710, 38.594, 42.356, 42.410, 50.041,59.419, 67.294, 73.330, 81.373, 88.431, 129.058, 137.093, 137.566, 151.134, 159.627, 166.403, 170.272, 178.010, 178.689, 218.285. This compound is 2b, see Figure 4.
In dimethyl sulfoxide at 20 - 58℃;
  • 8
  • [ 6284-40-8 ]
  • [ 19545-26-7 ]
  • WmC20-N-methyl-glucamine [ No CAS ]
YieldReaction ConditionsOperation in experiment
98.7% In dimethyl sulfoxide; at 20℃; for 0.5h; WmC20-N-methyl-glucamine was prepared by combining wortmannin(21.4 mg, 0.05 mmol) and N-methyl-glucamine (19.5 mg, 0.1 mmol) in anhydrous DMSO (0.5 mL) at room temperature with stirring for 0.5 hours. The product was purified by HPLC and lyophilized. Yield 30.7 mg, 98.7%. A BSA wortmannin conjugate can be prepared by combining WmC20- N-methyl-glucamine (2.4 mg, 3.79chilO~3 mmol) with BSA (25 mg, 3.79xlO"4 mmol) in phosphate buffered saline (0.4 mL) at 37" C with stirring overnight. The mixture can be purified by size exclusion chromatography. The ratio of Wm to BSA in the product can be calculated using a standard curve.; A mixture of wortmannin (21.4 mg, 0.05 mmol) andN-methyl glucamine (19.5 mg, 0.1 mmol) in anhydrous DMSO (0.5 mL) was stirred at room temperature for 0.5 hours. The mixture was purified by HPLC. A yellow powder, termed WmC20N(Me) glucamine, was obtained after lyophilization. Yield, 30.7mg, 98.7%. A solution of Erbitux (aka cetuximab, 30mg) and WmC20N(Me)glucamine (1.36 mg, 2.18xlO'3 mmol) were combined in PBS (5 mL) at 37 C for 20 hours. Unreacted WmC20N(Me)glucamine was removed with a Sephadex G-50 column in ImM phosphate buffer at pH 7. After lyophilization, a yellow powder was obtained. The ratio of Wm to cetuximab (6.0 Wm/mole) was obtained from the absorbances of certuximab at 280nm and conjugated Wm at 408 ran. The coupling efficiency was 55%. The WmC20-centuximab can be checked for immunoreactivity by using A549 cells and erbitux.
  • 9
  • [ 1121-58-0 ]
  • [ 19545-26-7 ]
  • [ 1046116-53-3 ]
YieldReaction ConditionsOperation in experiment
40% In dichloromethane at 20℃; for 15h;
Same Skeleton Products
Historical Records